Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 9/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9585006 | 0.94 | ALDH1A1 (0.45) | ALDH1A1SLC6A4LTA4HPPARGPPARA | |
| SCHEMBL8653942 | 0.93 | SLC6A4 (0.46) | ALDH1A1SLC6A4LTA4HPPARGPPARA | |
| SCHEMBL9584268 | 0.92 | SLC6A4 (0.58) | SLC6A4LTA4HCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1465631 | 0.86 | TAAR1 (0.44) | ALDH1A1SLC6A4PPARGPPARACYP2D6 | |
| SCHEMBL9584068 | 0.86 | SLC6A4 (0.51) | SLC6A4CYP1A2CYP2D6CYP2C19LMNA | |
| SCHEMBL1153290 | 0.83 | KDM4E (0.69) | ALDH1A1SLC6A4LTA4HPPARGPPARA | |
| SCHEMBL1153287 | 0.83 | KDM4E (0.69) | ALDH1A1SLC6A4LTA4HPPARGPPARA | |
| SCHEMBL1465792 | 0.83 | KDM4E (0.61) | SLC6A4CYP2D6KDM4ELMNAMAPK1 | |
| SCHEMBL636098 | 0.80 | SLC6A4 (0.51) | ALDH1A1SLC6A4LTA4HPPARGPPARA | |
| SCHEMBL5479687 | 0.78 | KIF11 (0.43) | ALDH1A1SLC6A4CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-12-09 | — | — | US | claimed |
| EP-2215101-A1 | CATIONIC TRANSITION METAL CATALYSTS | Kanata Chemical Technologies Inc. (CA) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055912-A1 | CATIONIC TRANSITION METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2009-05-07 | — | — | WO | claimed |
| US-5763688-A | HYDROGENATING A CARBONYL COMPOUND, RUTHENIUM-PHOSPHINE COMPLEX CATALYST, BASE, DIAMINE | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1998-06-09 | — | — | US | claimed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-5780692-A | CATALYTIC ASYMMETRIC HYDROGENATION OF A BENZOPHENONE; SIMPLIFICATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5756863-A | Process for preparing optically active cyclohexanol derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0781749-A2 | Process for producing optically active benzhydrol compounds | Takasago International Corporation (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0768288-A2 | Process for preparing optically active cyclohexanol derivatives | Takasago International Corporation (JP) | 1997-04-16 | — | — | EP | disclosed |
| EP-0718265-A2 | Method for producing an alcohol | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5238955-A | Anticarcinogenic agents | ASTA PHARMA AG (DE) | 1993-08-24 | — | — | US | disclosed |
| US-5194644-A | Antitumor agents; treatment of leukemia | ASTA PHARMA AG (DE) | 1993-03-16 | — | — | US | disclosed |
| EP-0451753-A1 | In the ethylenic moiety substituted phenylalkylethylenediamine-platinum (II or IV) derivatives and phenylalkyl-ethylenediamines | ASTA Medica Aktiengesellschaft (DE) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | ALDH1A1 6/4885SLC6A4 3240/4885LTA4H 1214/4885 |
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | ALDH1A1 1036/4885SLC6A4 1615/4885LTA4H 1564/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | ALDH1A1 1036/4885SLC6A4 1615/4885LTA4H 1564/4885 |
| US-20100311975-A1 | CATIONIC TRANSITION METAL CATALYSTS | AP2M1, OPRM1, CD81 | ALDH1A1 3759/4885SLC6A4 1993/4885LTA4H 3986/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | ALDH1A1 1036/4885SLC6A4 1615/4885LTA4H 1564/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | ALDH1A1 1036/4885SLC6A4 1615/4885LTA4H 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.